BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 14532988)

  • 1. Bcl-2 expression is a prognostic factor in the subgroups of patients with colorectal cancer.
    Sun XF; Bartik Z; Zhang H
    Int J Oncol; 2003 Nov; 23(5):1439-43. PubMed ID: 14532988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
    Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
    Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach.
    Tornillo L; Lugli A; Zlobec I; Willi N; Glatz K; Lehmann F; Spichtin HP; Maurer R; Stoios D; Sauter G; Terracciano L
    Am J Clin Pathol; 2007 Jan; 127(1):114-23. PubMed ID: 17145638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of ras is an independent prognostic factor in colorectal adenocarcinoma.
    Sun XF; Ekberg H; Zhang H; Carstensen JM; Nordenskjöld B
    APMIS; 1998 Jun; 106(6):657-64. PubMed ID: 9725799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome.
    Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD
    Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of Bcl-2, Bcl-XL and p53 in colorectal cancer.
    Han HS; Park YM; Hwang TS
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1108-14. PubMed ID: 16824061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of bcl-2 in Dukes' stage B and C colorectal carcinoma patients: correlation with p53 and ki-67 in evaluating prognostic significance.
    Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
    Pol J Pathol; 2005; 56(4):179-85. PubMed ID: 16477877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers.
    Krajewska M; Kim H; Kim C; Kang H; Welsh K; Matsuzawa S; Tsukamoto M; Thomas RG; Assa-Munt N; Piao Z; Suzuki K; Perucho M; Krajewski S; Reed JC
    Clin Cancer Res; 2005 Aug; 11(15):5451-61. PubMed ID: 16061861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential role of bcl-2 expression and apoptotic body index in colorectal cancer.
    El-Awady S; Morshed M; El-Shobaky M; Abo-Hashem M; Ghazy H
    Hepatogastroenterology; 2008; 55(81):76-81. PubMed ID: 18507083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Fas ligand and bcl-2 in cervical carcinoma and their prognostic significance.
    Munakata S; Watanabe O; Ohashi K; Morino H
    Am J Clin Pathol; 2005 Jun; 123(6):879-85. PubMed ID: 15899779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
    Ioachim E
    Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma.
    Allal AS; Waelchli L; Bründler MA
    Clin Cancer Res; 2003 Dec; 9(17):6489-96. PubMed ID: 14695153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma.
    Santini D; Tonini G; Vecchio FM; Borzomati D; Vincenzi B; Valeri S; Antinori A; Castri F; Coppola R; Magistrelli P; Nuzzo G; Picciocchi A
    J Clin Pathol; 2005 Feb; 58(2):159-65. PubMed ID: 15677536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas.
    Kato K; Kawashiri S; Yoshizawa K; Kitahara H; Yamamoto E
    J Oral Pathol Med; 2008 Jul; 37(6):364-71. PubMed ID: 18410312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bio-pathological factors of prognostic value in colorectal adenocarcinomas.
    Mottolese M; Buglioli S; Piperno G; Sperduti I; Giannarelli D; D'Angelo C; Cosimelli M
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):163-6. PubMed ID: 16767924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular markers in gastric cancer: can p53 and bcl-2 protein expressions be used as prognostic factors?
    Zafirellis K; Karameris A; Milingos N; Androulakis G
    Anticancer Res; 2005; 25(5):3629-36. PubMed ID: 16101192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour 'budding' and its relationship to p53 and Bcl-2 expression in colorectal cancer.
    Guzińska-Ustymowicz K; Sulkowska M; Famulski W; Sulkowski S
    Anticancer Res; 2003; 23(1B):649-53. PubMed ID: 12680162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.